An observational study of liraglutide in treating patients with polycystic ovary syndrome complicated with insulin resistance

Abstract:

Objective：To observe the effect of liraglutide on metabolic and endocrine parameters in patients with polycystic ovary syndrome（PCOS） complicated with insulin resistance（IR），and evaluate the efficacy of liraglutide in the treatment of PCOS. Methods：Before-after study method was adopted，32 normal people were randomly selected as controls and 23 patients with PCOS complicated with IR were treated with liraglutide 1.8 mg/d. General conditions and metabolic indicators including oral glucose tolerance test，in－sulin release test，HbA1c，blood fat and sex hormones were measured before treatment and 24 weeks after treatment. Euglycemic-hy－perinsulinemic clamp was performed before treatment and 24 weeks after treatment，and M values were recorded. Results：After treat－ment with liraglutide in patients with complications of PCOS and IR，their weight，body mass index，body fat content，waist circumfer－ence，hip circumference，glycosylated hemoglobin and insulin resistance index were lower than those before treatment（P<0.05）；serum testosterone，fasting insulin，total cholesterol，triacylglycerol and low density lipoprotein cholestorol were decreased than those before treatment（P<0.05）. M value was higher than that before treatment（P<0.05）；free androgen index（FAI） after treatment was decreased when compared with that before treatment. In PCOS patients，FAI was positively correlated with body weight，waist circumference，hip circumference and testesterone，and negatively correlated with sex hormone binding globulin（SHBG）. Multiple stepwise linear regression analysis showed that FAI in PCOS patients was correlated with testesterone and SHBG. Conclusion：Liraglutide can improve body weight，blood glucose，insulin resistance and hyperandro－genism in patients with complications of PCOS and IR.